S&P 500   4,589.37 (+0.88%)
DOW   36,152.44 (+0.27%)
QQQ   390.73 (+1.48%)
AAPL   194.30 (+1.03%)
MSFT   370.84 (+0.55%)
META   327.15 (+3.06%)
GOOGL   137.22 (+5.54%)
AMZN   146.94 (+1.67%)
TSLA   241.17 (+0.75%)
NVDA   464.68 (+2.12%)
NIO   7.53 (-2.84%)
BABA   72.23 (+1.04%)
AMD   127.77 (+9.37%)
T   17.08 (+0.83%)
F   10.83 (+1.31%)
MU   73.86 (+1.00%)
CGC   0.73 (+4.36%)
GE   119.07 (-0.62%)
DIS   92.68 (+1.29%)
AMC   6.88 (+1.33%)
PFE   28.82 (+0.10%)
PYPL   58.85 (-1.14%)
XOM   98.49 (-0.63%)
S&P 500   4,589.37 (+0.88%)
DOW   36,152.44 (+0.27%)
QQQ   390.73 (+1.48%)
AAPL   194.30 (+1.03%)
MSFT   370.84 (+0.55%)
META   327.15 (+3.06%)
GOOGL   137.22 (+5.54%)
AMZN   146.94 (+1.67%)
TSLA   241.17 (+0.75%)
NVDA   464.68 (+2.12%)
NIO   7.53 (-2.84%)
BABA   72.23 (+1.04%)
AMD   127.77 (+9.37%)
T   17.08 (+0.83%)
F   10.83 (+1.31%)
MU   73.86 (+1.00%)
CGC   0.73 (+4.36%)
GE   119.07 (-0.62%)
DIS   92.68 (+1.29%)
AMC   6.88 (+1.33%)
PFE   28.82 (+0.10%)
PYPL   58.85 (-1.14%)
XOM   98.49 (-0.63%)
S&P 500   4,589.37 (+0.88%)
DOW   36,152.44 (+0.27%)
QQQ   390.73 (+1.48%)
AAPL   194.30 (+1.03%)
MSFT   370.84 (+0.55%)
META   327.15 (+3.06%)
GOOGL   137.22 (+5.54%)
AMZN   146.94 (+1.67%)
TSLA   241.17 (+0.75%)
NVDA   464.68 (+2.12%)
NIO   7.53 (-2.84%)
BABA   72.23 (+1.04%)
AMD   127.77 (+9.37%)
T   17.08 (+0.83%)
F   10.83 (+1.31%)
MU   73.86 (+1.00%)
CGC   0.73 (+4.36%)
GE   119.07 (-0.62%)
DIS   92.68 (+1.29%)
AMC   6.88 (+1.33%)
PFE   28.82 (+0.10%)
PYPL   58.85 (-1.14%)
XOM   98.49 (-0.63%)
S&P 500   4,589.37 (+0.88%)
DOW   36,152.44 (+0.27%)
QQQ   390.73 (+1.48%)
AAPL   194.30 (+1.03%)
MSFT   370.84 (+0.55%)
META   327.15 (+3.06%)
GOOGL   137.22 (+5.54%)
AMZN   146.94 (+1.67%)
TSLA   241.17 (+0.75%)
NVDA   464.68 (+2.12%)
NIO   7.53 (-2.84%)
BABA   72.23 (+1.04%)
AMD   127.77 (+9.37%)
T   17.08 (+0.83%)
F   10.83 (+1.31%)
MU   73.86 (+1.00%)
CGC   0.73 (+4.36%)
GE   119.07 (-0.62%)
DIS   92.68 (+1.29%)
AMC   6.88 (+1.33%)
PFE   28.82 (+0.10%)
PYPL   58.85 (-1.14%)
XOM   98.49 (-0.63%)

Crinetics Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CRNX)

$33.50
+0.27 (+0.81%)
(As of 02:09 PM ET)
Compare
Today's Range
$32.82
$33.65
50-Day Range
$25.62
$33.50
52-Week Range
$15.23
$34.09
Volume
193,054 shs
Average Volume
769,292 shs
Market Capitalization
$2.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.38

Crinetics Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.7% Upside
$44.38 Price Target
Short Interest
Healthy
9.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.32mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$6.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.66) to ($3.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

119th out of 958 stocks

Pharmaceutical Preparations Industry

29th out of 396 stocks


CRNX stock logo

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock Price History

CRNX Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Crinetics Pharmaceuticals: Some Caution Warranted
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
8 Analysts Have This to Say About Crinetics Pharmaceuticals
11 Analysts Have This to Say About Crinetics Pharmaceuticals
See More Headlines
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.38
High Stock Price Target
$56.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+33.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-163,920,000.00
Net Margins
-4,223.27%
Pretax Margin
-4,202.16%

Debt

Sales & Book Value

Annual Sales
$4.74 million
Book Value
$5.88 per share

Miscellaneous

Free Float
62,123,000
Market Cap
$2.22 billion
Optionable
Not Optionable
Beta
0.55
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. R. Scott Struthers Ph.D. (Age 61)
    Founder, President, CEO & Director
    Comp: $870.69k
  • Dr. Stephen F. Betz Ph.D. (Age 57)
    Founder & Chief Scientific Officer
    Comp: $618.58k
  • Mr. Marc J. C. Wilson (Age 44)
    Chief Financial Officer
    Comp: $585.54k
  • Mr. James Hassard (Age 57)
    Chief Commercial Officer
    Comp: $513.34k
  • Dr. Dana Pizzuti M.D. (Age 67)
    Chief Development Officer
    Comp: $493.62k
  • Mr. Jeff E. Knight (Age 52)
    Chief Operating Officer
    Comp: $237.64k
  • Ms. Garlan Adams
    General Counsel & Corporate Secretary
  • Ms. Adriana Cabre M.B.A.
    Chief Human Resources Officer
  • Dr. Alan S. Krasner M.D. (Age 60)
    Chief Medical Officer
    Comp: $571.97k
  • Mr. Kevin Capps
    Head of Intellectual Property














CRNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price target for 2024?

9 equities research analysts have issued 12 month price objectives for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $33.00 to $56.00. On average, they anticipate the company's stock price to reach $44.38 in the next year. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2023?

Crinetics Pharmaceuticals' stock was trading at $18.30 at the start of the year. Since then, CRNX stock has increased by 80.1% and is now trading at $32.95.
View the best growth stocks for 2023 here
.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 6,200,000 shares, a drop of 7.6% from the October 31st total of 6,710,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio is currently 4.0 days.
View Crinetics Pharmaceuticals' Short Interest
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.12. The firm had revenue of $0.35 million for the quarter. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 57.04% and a negative net margin of 4,223.27%.

What ETF holds Crinetics Pharmaceuticals' stock ?

iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (5.45%), FMR LLC (3.20%), Jennison Associates LLC (2.62%), Eventide Asset Management LLC (1.53%), Avidity Partners Management LP (0.91%) and Northern Trust Corp (0.89%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CRNX) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -